Century Therapeutics, Inc. Operating Expenses
Century Therapeutics, Inc. (IPSC) reported Operating Expenses of $36.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Century Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $36.53M, a 5.37% increase year-over-year.
- Century Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $23.68M, a 32.31% decline year-over-year.
- Century Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $20.65M, a 50.19% decline year-over-year.
- Century Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $36.12M, a 1.53% increase year-over-year.
- Century Therapeutics, Inc. operating expenses for fiscal 2025 was $126.43M, a 12.64% decline from fiscal 2024.
- Century Therapeutics, Inc. operating expenses for fiscal 2024 was $144.73M, a 2.73% decline from fiscal 2023.
- Century Therapeutics, Inc. operating expenses for fiscal 2023 was $148.78M, a 7.01% increase from fiscal 2022.
- Century Therapeutics, Inc. operating expenses for fiscal 2022 was $139.03M, a 46.53% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.53M 10-Q · filed 2026-08-12 | $60.21M 10-Q · filed 2026-08-12 | $80.86M derived: sum of 3 quarters · filed 2026-08-12 | $116.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $23.68M 10-Q · filed 2026-05-13 | $44.34M derived: sum of 2 quarters · filed 2026-05-13 | $80.46M derived: sum of 3 quarters · filed 2026-05-13 | $115.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $20.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $56.77M derived: sum of 2 quarters · filed 2026-03-12 | $91.44M derived: sum of 3 quarters · filed 2026-08-12 | $126.43M 10-K · filed 2026-03-12 |
| 2025-09-30 | $36.12M 10-Q · filed 2025-11-13 | $70.79M derived: sum of 2 quarters · filed 2026-08-12 | $105.78M 10-Q · filed 2025-11-13 | $147.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $34.66M 10-Q · filed 2026-08-12 | $69.65M 10-Q · filed 2026-08-12 | $111.11M derived: sum of 3 quarters · filed 2026-08-12 | $146.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $34.99M 10-Q · filed 2026-05-13 | $76.44M derived: sum of 2 quarters · filed 2026-05-13 | $112.03M derived: sum of 3 quarters · filed 2026-05-13 | $147.55M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $41.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $77.04M derived: sum of 2 quarters · filed 2026-03-12 | $112.56M derived: sum of 3 quarters · filed 2026-03-12 | $144.73M 10-K · filed 2026-03-12 |
| 2024-09-30 | $35.58M 10-Q · filed 2025-11-13 | $71.11M derived: sum of 2 quarters · filed 2025-11-13 | $103.27M 10-Q · filed 2025-11-13 | $147.30M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $35.53M 10-Q · filed 2025-08-14 | $67.69M 10-Q · filed 2025-08-14 | $111.72M derived: sum of 3 quarters · filed 2025-08-14 | $147.49M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $32.16M 10-Q · filed 2025-05-15 | $76.19M derived: sum of 2 quarters · filed 2025-05-15 | $111.97M derived: sum of 3 quarters · filed 2025-05-15 | $147.14M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $44.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $79.80M derived: sum of 2 quarters · filed 2025-03-19 | $114.98M derived: sum of 3 quarters · filed 2025-03-19 | $148.78M 10-K · filed 2025-03-19 |
| 2023-09-30 | $35.77M 10-Q · filed 2024-11-05 | $70.95M derived: sum of 2 quarters · filed 2024-11-05 | $104.75M 10-Q · filed 2024-11-05 | $138.58M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $35.18M 10-Q · filed 2024-08-08 | $68.98M 10-Q · filed 2024-08-08 | $102.80M derived: sum of 3 quarters · filed 2024-08-08 | $136.77M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $33.80M 10-Q · filed 2024-05-09 | $67.63M derived: sum of 2 quarters · filed 2024-05-09 | $101.59M derived: sum of 3 quarters · filed 2024-05-09 | $134.34M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $33.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $67.79M derived: sum of 2 quarters · filed 2024-03-14 | $100.54M derived: sum of 3 quarters · filed 2024-03-14 | $139.03M 10-K · filed 2024-03-14 |
| 2022-09-30 | $33.96M 10-Q · filed 2023-11-09 | $66.71M derived: sum of 2 quarters · filed 2023-11-09 | $105.20M 10-Q · filed 2023-11-09 | $133.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $32.75M 10-Q · filed 2023-08-09 | $71.24M 10-Q · filed 2023-08-09 | $99.21M derived: sum of 3 quarters · filed 2023-08-09 | $125.04M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $38.49M 10-Q · filed 2023-05-11 | $66.47M derived: sum of 2 quarters · filed 2023-05-11 | $92.29M derived: sum of 3 quarters · filed 2023-05-11 | $115.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $53.80M derived: sum of 2 quarters · filed 2023-03-16 | $76.82M derived: sum of 3 quarters · filed 2023-03-16 | $94.88M 10-K · filed 2023-03-16 |
| 2021-09-30 | $25.83M 10-Q · filed 2022-11-10 | $48.85M derived: sum of 2 quarters · filed 2022-11-10 | $66.91M 10-Q · filed 2022-11-10 | $82.17M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $23.02M 10-Q · filed 2022-08-11 | $41.08M 10-Q · filed 2022-08-11 | $56.34M derived: sum of 3 quarters · filed 2022-08-11 | $69.47M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $18.06M 10-Q · filed 2022-05-16 | $33.32M derived: sum of 2 quarters · filed 2022-05-16 | $46.45M derived: sum of 3 quarters · filed 2022-05-16 | $61.97M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $28.39M derived: sum of 2 quarters · filed 2022-03-17 | $43.91M derived: sum of 3 quarters · filed 2022-03-17 | $53.90M 10-K · filed 2022-03-17 |
| 2020-09-30 | $13.13M 10-Q · filed 2021-11-10 | $28.65M derived: sum of 2 quarters · filed 2021-11-10 | $38.64M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $15.52M 10-Q · filed 2021-08-12 | $25.51M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |